advisory board

Frank Pieters, CEO P&L Projects, chairman of the board at Softhale NV, head of strategy and business development at Aquilon.

Didier Cataldo is a clinician pneumologist and ordinary Professor at the University of Liege. He manages a research lab at university of Liege focused on the mechanisms of asthma, COPD and lung cancer/mesothelioma progression. Many different tools are available in his lab to study mechanisms of action of various experimental drugs in vitro and in animal models. He is the chairman of the scientific advisory board at Aquilon and member of the Académie Royale de Médecine de Belgique.

Stefano Console has more than 25 years of experience in the pharmaceutical and fine chemical business. The broad experience gathered with different CDMOs (Contract Development & Manufacturing Organizations) in Italy and Switzerland covered strategic roles managing a large number of successful projects for big as well as small Pharma partners across EU, USA and Japan. Currently Stefano is Senior Advisor at Oriento SA, a Swiss based advisory firm.

Pietro Crovetto worked in General Management, Marketing, and Business Development in several blue chip pharma companies, like GSK, Novartis, Chiesi, Teva, Lupin. In these positions he has acquired a deep understanding of the issues connected with the development and marketing of respiratory products and delivery devices like pMDI, DPI and ADI (aerosol, powder, and aqueous inhalers), in licensing and out licensing product and medical technologies, industrialisation of both devices and products, and development of strategic alliances worldwide.

Marc Dechamps is a biologist with extensive experience of more than 30 years in the Pharmaceutical and Biotech industry. Marc was subsequently Executive Director Commercial department “Specialty care & Vaccines” at GSK Belgium, Head of European Mid-Size Countries at ViiV Healthcare (ViiVHC) and Head of ViiVHC European Commercial – Market Access Operations team. Recently Marc was CEO of eTheRNA, Immunotherapies, a clinical stage Biotech company involved in Immuno-oncology. Marc is now Director International Affairs at BioWin the health cluster of Wallonia.

Marc Decramer is a pneumologist at UZ Leuven, professor at the KUL Faculty of Medicine and Managing Director at UZ Leuven.

René Deman is Pneumologist and Head of the Department of Respiratory Medicine at AZ Groeninge ( Kortrijk – Belgium ) . He has a broad interest in the field of astma , COPD en sleep medicine

Guy Joos is Pneumologist and Head of the Dept of Respiratory Medicine at Ghent University Hospital. He is full Professor at Ghent University and Director of Research at the Faculty of Medicine and Health Sciences of Ghent University.

Gudrun Koppen is an Engineer in Chemistry and Agricultural Sciences. Since 1999 she works at the Flemish Institute of Technological Research (VITO, Belgium), in the unit Environmental Risk and Health. She mainly performs project work in the field of ‘human biomonitoring’. Tasks include WP coordination, study design, logistics, data interpretation, statistics and reporting. In this context she has more than 20 year experience in molecular epidemiology, and biomarker development in the areas of genotoxicity, inflammation and oxidative stress.

Robert Lins is a results-focused manager with a strong entrepreneurial spirit and extensive experience in the health care sector. Strong experience as a physician-specialist and as general manager in hospital sector, in hospital clinical research, in clinical research organisation, and as consultant to pharmaceutical industry

Hans Luijendijk is an experienced Life Sciences executive. Has led one of the priority Therapeutic Areas of Teva. Currently leads Development of commercial processes and structures to improve value and competitiveness of assets in development, as well as improving ROI for in line brands.

Julie D. Suman is co-founder and President of Next Breath, an Aptar Pharma Company. Next Breath is a contract research organization dedicated to the development and analytical testing of nasal, inhalation and injectable delivery systems. Dr. Suman directs the research division that supports product development and regulatory submissions for North American and International Clients in the pharmaceutical, biotechnology and medical device markets.

Jan Van Meerbeeck is currently professor of Thoracic Oncology at both Ghent and Antwerp University and chair of the Pulmonology Department of the Antwerp Academic Hospital (UZA). His translational scientific interests include the molecular diagnosis of lung cancer and the evaluation of biomarkers of asbestos exposure and the management of mesothelioma. He is a full member of the ASCO and the IASLC, external expert at the Belgian HTA Knowledge Center KCE and he has an extensive presentation and publication track, with more than 300 peer-reviewed articles in oncology and pulmonology journals and textbooks.